Examkin

Question

Difficulty: Very hardRheumatology and Immunology

A 45-year-old woman is evaluated in the rheumatology clinic and newly diagnosed with highly active, seropositive rheumatoid arthritis (RA). Baseline radiographs reveal early marginal erosions in the metacarpophalangeal joints. Arrange the following clinical steps in the most appropriate chronological order for her long-term management, assuming she exhibits an inadequate response to each successive pharmacological intervention.

  1. 1Initiate methotrexate monotherapy with folic acid supplementation and a bridging course of oral glucocorticoids.
  2. 2Document failure to achieve target low disease activity on a validated composite measure after 3 months of optimal adherence.
  3. 3Perform an interferon-gamma release assay (IGRA) to screen for latent tuberculosis infection.
  4. 4Escalate pharmacological management by adding a tumor necrosis factor (TNF) inhibitor to the existing regimen.
  5. 5Transition to a biologic DMARD with a non-TNF mechanism of action, such as an IL-6 receptor antagonist.

Answer

The correct sequence is: Initiate methotrexate → Document failure at 3 months → Perform IGRA screening → Add a TNF inhibitor → Switch to a non-TNF biologic.
The treat-to-target approach for rheumatoid arthritis dictates a strict step-up algorithmic sequence. Initial management relies on conventional synthetic DMARDs, predominantly methotrexate, combined with short-term bridging glucocorticoids. Efficacy must be reassessed after 3 months. If target disease activity is not met, the regimen is escalated, typically by adding a first-line biologic DMARD such as a TNF inhibitor. Crucially, immediately prior to initiating any biologic DMARD, screening for latent tuberculosis with an IGRA is universally mandated to prevent life-threatening reactivation. Finally, if a patient fails to respond adequately to the primary TNF inhibitor, evidence-based guidelines recommend switching to a biologic DMARD utilizing a different mechanism of action, such as an IL-6 inhibitor or anti-CD20 monoclonal antibody.

Step-by-Step Solution

1
Initiate methotrexate with folic acid and bridging glucocorticoids.
First-line conventional synthetic DMARD (csDMARD) therapy is established.
Methotrexate is the standard of care initial therapy for all patients with newly diagnosed, active rheumatoid arthritis.
2
Evaluate disease activity after 3 months.
Failure to achieve low disease activity target is formally documented.
The 'treat-to-target' strategy requires reassessment at 3-6 months to objectively determine if medication escalation is necessary.
3
Perform an interferon-gamma release assay (IGRA).
Patient is screened and cleared for latent tuberculosis.
Latent TB screening is universally mandated before the initiation of any biologic DMARD due to the severe risk of disease reactivation.
4
Add a TNF inhibitor to the current regimen.
Patient is escalated to combination therapy (csDMARD + first-line biologic DMARD).
Addition of a TNF inhibitor is the standard initial biologic escalation step for patients failing methotrexate monotherapy.
5
Switch to an IL-6 receptor antagonist or other non-TNF biologic.
Patient is transitioned to a second-line biologic with a different mechanism.
Secondary loss of efficacy to a TNF inhibitor warrants switching to an agent with a non-TNF mechanism of action.

Key Concept

Sequential Treat-to-Target Management of Rheumatoid Arthritis
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic